Global Oncology Academy

Panel Discussion: A Focus on Emerging Treatment Options in Non-Small Cell Lung Cancer

Lung cancer is by far the leading cause of cancer death among both men and women, with non-small cell lung cancer being the most common type of lun...

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Lung cancer is by far the leading cause of cancer death among both men and women, with non-small cell lung cancer being the most common type of lung cancer at approximately 85%. This panel discussion will cover emerging treatment options for non-small cell lung cancer and the adverse events we need to be aware of prior to their use. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 

    Edward B. Garon, MD, MS
    Director of Thoracic Oncology
    David Geffen School of Medicine at UCLA
    Los Angeles, CA

    Faculty’s disclosure:
    Contracted Research: AstraZeneca, Bristol-Myers Squib, Boehringer Ingelheim, Genentech, Eli Lilly, Maruti Pharma, Merck, Novartis, Pfizer

    Blanca Ledezma, NP
    Nurse Practitioner
    UCLA Hematology-Oncology
    Santa Monica, CA

    Faculty’s disclosure:
    Commercial Interest Speakers Bureau: AstraZeneca    
    Consulting Fees: AstraZeneca

    Reviewers/Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has nothing to disclose.
  • Learning Objectives

    At the completion of this CME activity participants managing patients with NSCLC will be better able to:

    • Identify those patients suitable for first-line-line anti-PD-1 immunotherapy.
    • Understand under what conditions anti-PD-1 therapy might be used second-line following first-line chemotherapy or targeted therapy failure.
    • Recognize common adverse events associated with anti-PD-1 immunotherapy, and how best to manage them clinically.
    • Differentiate between immune-mediated pneumonitis and disease progression.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

NEW FEATURES: